| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
You are
here > Biopharmaceutical
Glossary
Homepage/Search Index > Newest biopharmaceutical definitions 21st
century Drug discovery & development Map
Informatics map Technologies
map Biology & chemistry map
Finding guide to terms in these glossaries Site
Map accelerator mass spectrometry: Mass spectrometry adaptive clinical trials: Clinical trials Bayesian clinical trials: Clinical trials biological chemistry: Chemistry (& biology) biomarker guidelines: Biomarkers biomathematics Algorithms biomedical polymers: Biomaterials biomolecular screening: Assays & screening cell specific biomarkers: Biomarkers cellular dielectric spectroscopy CDS: Technologies chaperome: -Omes & -omics Clinical Trial Design Task Force: Clinical Trials combination therapies: Drug Discovery & Development **comparative effectiveness research: Research comparative systems biology: Genomic Manipulation & Disruption computational physiology: Drug discovery informatics computational sensing: Labels Signaling & detection **connectome: -Omes & -omics Copy Number Polymorphisms CNPs: SNPs and Genetic Variations developability: Drug discovery & development diffusion tensor imaging: Molecular imaging disproportionate drug metabolite: Drug safety, Pharmacovigilance & toxicology drug metabolism: Pharmacogenomics eSNPs expression SNPs: SNPs and genetic variations evidence based toxicology: Drug safety, Pharmacovigilance & toxicology exploratory IND: Regulatory Affairs expressomics: -Omes & -omics follow-on drug: Drug discovery & development fragment based drug discovery Assays and screening genetic susceptibility: Molecular diagnostics -- genetic & genomic testing GIS Geographic Information Systems: Molecular Medicine and Diagnostics glycomimetics: Glycosciences green chemistry: Chemistry & biology GWAS
Genome Wide Association Sequencing: Genomic
informatics human induced pluripotent stem cells hiPS: Stem cells inflammasome: -Omes & -omics integrative and organ systems pharmacology: Pharmacogenomics ** in vitro adventitious assays: Assays & screening in vitro diagnostic multivariate index assays IVDMIAs: Genetic & genomic testing integrative biology: Pharmaceutical biology kidney safety biomarkers: Biomarkers label free detection: Labels Signaling & detection lead hopping: Assays lipidomics: 'Omes & 'omics mass spectrometry" IUPAC Mass Spectrometry Standard definitions of terms relating to mass spectrometry Provisional recommendations http://www.iupac.org/reports/provisional/abstract06/murray_prs.pdf materials chemistry: Chemistry & biology medical resequencing: Sequencing mesoscopic biology: Expression genes & proteins metabolite: Drug safety, Pharmacovigilance & toxicology microdosing Pharmacogenomics microtissues: Cell biology mitochondriomics: -Omes & -omics molecular biosensors: Labels Signaling & detection molecular crowding: Biomolecules molecular electronics: Nanoscience & miniaturization molecular events: Cancer diagnostics, genomics, prognostics & therapeutics molecular pharmacology Pharmacogenomics mRNA biomarkers: Biomarkers nanolabels: Labels Signaling & detection nanomedicine: Nanoscience & miniaturization nanotechnology in the clinical laboratory setting: Molecular Medicine natural competence: DNA network pharmacology: Pharmacogenomics next generation sequencing: Sequencing niche busters: Drug discovery & development -Omes & -omics: Lots of new terms including alleome, chromatinomics, chromosonics, cryobionomics, embryogenomics, epitomics, fragonomics, lectinomics, mitogenomics, Nobonomics, paleogenomics, RNome, RNomics, separomics, strainomics, transgenomics oncolytic: Cancer diagnostics, prognostics & therapeutics patient engagement: Molecular Medicine patient navigation: Cancer diagnostics, genomics, prognostics & therapeutics pharmacokinetics: Pharmacogenomics pharmacological biomarkers: Biomarkers pharmacologically active metabolite: Drug safety, Pharmacovigilance & toxicology Phase II clinical trial design: Clinical Trials Phase zero, Phase O: Drug approvals physiologically based pharmacodynamics: Pharmacogenomics pipeline problem: Drug discovery post-genomic chemistry: Chemistry & biology preclinical safety biomarkers: Biomarkers predictive ADME: Drug safety & pharmacovigilance predictive biomarkers: Biomarkers predictive toxicology: Drug safety, toxicology & pharmacovigilance process chemistry: Chemistry & biology Proteomic Standards Initiative: Proteomics quantitative
pharmacology: Pharmacogenomics resourceome: -Omes & -Omics ridiculome: -Omes & -Omics safety pharmacology: Drug Safety & Pharmacovigilance selection biomarkers: Biomarkers semantic systems biology: Genomic & Proteomic Manipulation & Disruption including RNAi seromics: See under autoantibodies: Cancer diagnostics & genomics small molecule biomarkers: Biomarkers solubility: Chemistry & biology supramolecular electronics: Nanoscience & miniaturization **synthetic biology: Drug discovery informatics systems pharmacology: Pharmacogenomics scaffold hopping: Chemistry Sentinel Initiative: Drug safety, toxicology & pharmacovigilance soft drug design: Molecular modeling target hopping: Drug targets therapeutic antibodies: Drug targets top-down mass spectrometry: Mass spectrometry translational biomarkers: Biomarkers translational pharmacodynamics: Pharmacogenomics type 0, type I, type II biomarkers: Biomarkers women's health: Molecular Medicine women's health statistical modeling: Molecular Medicine Bibliography
|
Contact
| Privacy Statement |
Alphabetical
Glossary List | Tips & glossary
FAQs | Site Map
